<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To describe characteristics and outcomes of <z:e sem="disease" ids="C0042384" disease_type="Disease or Syndrome" abbrv="">vasculitides</z:e> associated with <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The requirement for inclusion in this retrospective, 10-year study was development of <z:hpo ids='HP_0002633'>vasculitis</z:hpo> in patients with a progressing <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">Malignancies</z:e> secondary to <z:chebi fb="1" ids="35705">immunosuppressants</z:chebi> used to treat <z:hpo ids='HP_0002633'>vasculitis</z:hpo> were excluded </plain></SENT>
<SENT sid="3" pm="."><plain>The main characteristics of <z:e sem="disease" ids="C0042384" disease_type="Disease or Syndrome" abbrv="">vasculitides</z:e> were analyzed and compared according to the type of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Sixty patients were included (male/female sex ratio 2.53, mean age 62.4 years) </plain></SENT>
<SENT sid="5" pm="."><plain>Mean followup duration was 45.2 months </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0042384" disease_type="Disease or Syndrome" abbrv="">Vasculitides</z:e> were cutaneous leukocytoclastic (45%), <z:e sem="disease" ids="C0031036" disease_type="Disease or Syndrome" abbrv="">polyarteritis nodosa</z:e> (36.7%), Wegener's <z:hpo ids='HP_0002955'>granulomatosis</z:hpo> (6.7%), <z:e sem="disease" ids="C0343192" disease_type="Disease or Syndrome" abbrv="">microscopic polyangiitis</z:e> (5%), and Henoch-Sch√∂nlein <z:hpo ids='HP_0000979'>purpura</z:hpo> (5%) </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">Malignancies</z:e> were distributed as follows: hematologic in 63.1%, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) in 32.3%, lymphoid in 29.2%, and <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> in 36.9% </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C0042384" disease_type="Disease or Syndrome" abbrv="">Vasculitides</z:e> were diagnosed concurrently with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> in 38% of the cases </plain></SENT>
<SENT sid="9" pm="."><plain>Manifestations of <z:e sem="disease" ids="C0042384" disease_type="Disease or Syndrome" abbrv="">vasculitides</z:e> were <z:hpo ids='HP_0001945'>fever</z:hpo> (41.7%), cutaneous involvement (78.3%), <z:hpo ids='HP_0002829'>arthralgias</z:hpo> (46.7%), <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> (31.7%), renal involvement (23.3%; 11.7% <z:hpo ids='HP_0000099'>glomerulonephritis</z:hpo>, 11.7% <z:e sem="disease" ids="C0333101" disease_type="Disease or Syndrome" abbrv="">microaneurysms</z:e>, 6.7% <z:hpo ids='HP_0000083'>renal insufficiency</z:hpo>), and antineutrophil cytoplasmic antibody (20.4%) </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0002633'>Vasculitis</z:hpo> treatments were <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> (78.3%) and <z:chebi fb="1" ids="35705">immunosuppressant</z:chebi>(s) (41.7%) </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0002633'>Vasculitis</z:hpo> was cured in 65% of patients, but 58.3% died, with 1 <z:hpo ids='HP_0011420'>death</z:hpo> secondary to <z:hpo ids='HP_0002633'>vasculitis</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Independent of subtype, patients with <z:e sem="disease" ids="C0042384" disease_type="Disease or Syndrome" abbrv="">vasculitides</z:e> associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> more frequently had renal manifestations (P = 0.02) and steroid dependence (P = 0.04) and achieved complete remission less often (P = 0.04) than patients with <z:e sem="disease" ids="C0042384" disease_type="Disease or Syndrome" abbrv="">vasculitides</z:e> associated with other <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>Patients with <z:e sem="disease" ids="C0042384" disease_type="Disease or Syndrome" abbrv="">vasculitides</z:e> associated with a <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> more frequently had peripheral neurologic involvement (P = 0.05) </plain></SENT>
<SENT sid="14" pm="."><plain>Patients with <z:e sem="disease" ids="C0042384" disease_type="Disease or Syndrome" abbrv="">vasculitides</z:e> associated with lymphoid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> had less frequent <z:hpo ids='HP_0002829'>arthralgias</z:hpo> (P = 0.01) and renal involvement (P = 0.02) </plain></SENT>
<SENT sid="15" pm="."><plain>CONCLUSION: <z:e sem="disease" ids="C0042384" disease_type="Disease or Syndrome" abbrv="">Vasculitides</z:e> occurring during <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> present distinctive features according to the <z:hpo ids='HP_0002633'>vasculitis</z:hpo> subtype and nature of the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
</text></document>